Department of Nephrology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Key Laboratory of Kidney Disease of Traditional Chinese Medicine in Zhejiang Province, Hangzhou, Zhejiang, P. R. China.
Eur Rev Med Pharmacol Sci. 2019 Feb;23(4):1652-1660. doi: 10.26355/eurrev_201902_17126.
We conducted a meta-analysis on exploring the correlation between I/D polymorphism of ACE and risk of diabetes mellitus-related end-stage renal disease.
Researches on the correlation between I/D polymorphism of ACE and the risk of diabetes-related end-stage renal disease were searched in the three online databases (PubMed, Embase, and Cochrane Library). Citations of related researches were manually examined and enrolled. This study systematically searched relative literature for cohort studies or case-control studies published in the English language until December 1, 2018. Researches containing odds ratio (OR) and 95% confidence interval (CI) calculated based on the correlation between I/D polymorphism of ACE and the risk of diabetes-related end-stage renal disease were enrolled. The included data were weighted by an inverse variance and then analyzed by a fixed or random effects model. Researches met the inclusion criteria were extracted for relevant data and subjected to a heterogeneity test. The effect size was calculated by STATA 12.0 software for meta-analysis.
A total of 15 articles including 1199 cases of diabetes-related end-stage renal disease and 2939 cases of controls were enrolled. I/D polymorphism of ACE remarkably increased the risk of diabetes-related end-stage renal disease. In the subgroup analysis by ethnicity, a significant difference in risk of diabetes-related ESRD was only detected in the Asian population with I/D polymorphism of ACE. However, no significant difference in disease risk was found in the Caucasian population.
This meta-analysis suggested that I/D polymorphism of ACE can markedly increase the incidence of diabetes-related end-stage renal disease, especially in Asian populations.
我们进行了荟萃分析，以探讨 ACE I/D 多态性与糖尿病相关终末期肾病风险之间的相关性。
在三个在线数据库（PubMed、Embase 和 Cochrane Library）中搜索 ACE I/D 多态性与糖尿病相关终末期肾病风险之间相关性的研究。手动检查并纳入相关研究的引文。本研究系统地搜索了截至 2018 年 12 月 1 日以英语发表的关于队列研究或病例对照研究的相关文献。纳入的研究包含根据 ACE I/D 多态性与糖尿病相关终末期肾病风险之间的相关性计算出的优势比（OR）和 95%置信区间（CI）。使用逆方差对包含的数据进行加权，然后使用固定或随机效应模型进行分析。纳入符合纳入标准的研究以提取相关数据并进行异质性检验。使用 STATA 12.0 软件计算荟萃分析的效应量。
共纳入 15 篇文章，包括 1199 例糖尿病相关终末期肾病和 2939 例对照。ACE I/D 多态性显著增加了糖尿病相关终末期肾病的风险。在按种族进行的亚组分析中，仅在 ACE I/D 多态性的亚洲人群中发现糖尿病相关 ESRD 的风险存在显著差异。然而，在白种人群中未发现疾病风险存在显著差异。
本荟萃分析表明，ACE I/D 多态性可显著增加糖尿病相关终末期肾病的发生率，尤其是在亚洲人群中。
